基本信息
views: 293
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Infection with hepatitis B and C viruses affects more than 10 percent of the world population and is the most common etiology of chronic liver disease and hepatocellular carcinoma, which is the fourth leading cause of death from cancer in the world. Current therapies for both viruses are less than optimal. While an effective vaccine for HBV is available, the prospect for a HCV vaccine remains elusive. Given the magnitude and severity of both viral infections as a global public health problem, it is imperative to develop and implement effective prophylactic vaccines and better therapeutic regimens. To achieve this goal, we must understand at the molecular, cellular and genetic levels the viral life cycle, viral mechanisms for productive and persistent infection, virus-host interactions, and host immune responses. The thematic effort of my laboratory focuses on these topics.
Building on our extensive experiences in antiviral development, we have also established an active research program on therapeutic development of COVID-19, with focus on the entry/fusion process of infection.
Finally, we have established an active research program on the increasingly important problem of hepatocellular carcinoma in the context of chronic viral hepatitis. We are developing various in vitro and in vivo models to identify and study potentially important pro-carcinogenic pathways that are triggered by HBV or HCV infection. By leveraging this knowledge, we hope to uncover novel strategies for preventive and therapeutic interventions of this deadly cancer.
Building on our extensive experiences in antiviral development, we have also established an active research program on therapeutic development of COVID-19, with focus on the entry/fusion process of infection.
Finally, we have established an active research program on the increasingly important problem of hepatocellular carcinoma in the context of chronic viral hepatitis. We are developing various in vitro and in vivo models to identify and study potentially important pro-carcinogenic pathways that are triggered by HBV or HCV infection. By leveraging this knowledge, we hope to uncover novel strategies for preventive and therapeutic interventions of this deadly cancer.
Research Interests
Papers共 574 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Methods in molecular biology (Clifton, N.J.) (2024): 1-9
Authorea (Authorea) (2023)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americano. Suppl 3 (2023): S257-S261
Hepatology (Baltimore, Md.)no. 3 (2023): 929-942
Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americano. Supplement_3 (2023): S216-S223
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn